“…A strategy used to design new chemotherapeutics candidates and improve its anti-tumoral activity, consists on the complexation of some metallic centers, among them, silver (I) (Ali et al, 2013; Engelbrecht et al, 2018; Hussaini et al, 2019), gold (I)/(III) (Yeo et al, 2018; Dabiri et al, 2019; Hussaini et al, 2019), copper (II) (Khan et al, 2017; Zhang et al, 2018; Chen et al, 2019), and platinum (II) (Hua et al, 2019; Hussaini et al, 2019; Makovec, 2019) with a wide-range of ligands and also with natural molecules that already demonstrate some anti-cancer features, such as quinoline, flavones, and naphthoquinones (Kosmider and Osiecka, 2004; Lu et al, 2016; Oliveira et al, 2017a; Wang et al, 2018; Grandis et al, 2019). In this scenario, ruthenium takes special interests due to the possibility to reach several different metallic-arrangements, supplying distinct reactivities and applications (Oliveira et al, 2017b; Hussaini et al, 2019; Roy et al, 2019).…”